Choline supplementation to prevent fetal overgrowth in gestational diabetes
Research collaboration to validate maternal choline supplementation (MCS) as a nutritional intervention that normalizes placental nutrient transport and reduces fetal overgrowth risk in pregnancies complicated by gestational diabetes mellitus (GDM), potentially lowering lifelong cardiometabolic disease risk in offspring.
Overview
Gestational diabetes mellitus (GDM) doubles the risk of fetal overgrowth, predisposing affected infants to cardiometabolic diseases later in life. This research proposes maternal choline supplementation (MCS) as a nutritional intervention to normalize placental fat and glucose transport in GDM-complicated pregnancies, thereby reducing the risk of delivering large-for-gestational-age (LGA) neonates. Choline is a naturally occurring nutrient found in egg yolks, meat, fish, and cruciferous vegetables that plays critical roles in lipid metabolism and methyl group provision for epigenetic modification. The study addresses a significant unmet need in maternal-fetal health by targeting placental dysfunction, the underlying mechanism of GDM-related fetal overgrowth.
Technical specifications
The research builds on prior animal and cell-line findings demonstrating that MCS at four times standard intake (2 g/kg diet) reduces expression of glucose and fatty acid transporters GLUT1 and FATP1 in the placenta. This reduction lowers placental glycogen and triglyceride storage and prevents fetal overgrowth through inhibition of the AKT/mTOR signaling pathway. Additional findings show that MCS normalizes fetal adiposity, liver fat accumulation, and placental junctional zone thickening in GDM mouse models. In human choriocarcinoma BeWo cells, MCS decreased glucose and fatty acid uptake into placental cells. The proposed human clinical trial will recruit 60 pregnant women with GDM at 28 weeks of gestation, randomizing them to receive either 470 mg choline supplement per day or placebo for 8 weeks. Investigators will measure neonatal birth weight, placental glucose and fat transporter expression, mTOR activity, and DNA methylation of metabolic genes in placenta and cord blood.
Technology readiness level
The intervention is currently at an early-to-mid stage of translational development. Preclinical validation has been completed in mouse models of GDM and in human placental cell lines (BeWo). The proposed randomized controlled human trial represents the next critical step toward clinical validation. The study is estimated to take one year to complete. The research team is seeking partnership support for study personnel, participant compensation, and assay reagents to conduct the clinical trial.
About Brooklyn College
Brooklyn College is a public liberal arts college within the City University of New York, serving a large, diverse student body on an urban campus. Corporate partners engage through shared CUNY core facilities, co-located labs, and access to incubators and research parks across New York City. The location enables agile sponsored research agreements, student internships, and workforce pipelines, with ready access to government agencies and a broad corporate base. Research is supported by competitive federal funding such as the National Science Foundation and the National Institutes of Health, alongside state, city, and philanthropic sponsors. A centralized CUNY technology transfer office supports IP, licensing, and startup formation.
delivered to your inbox.